In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
24 01 2019
Historique:
pubmed: 5 12 2018
medline: 18 10 2019
entrez: 5 12 2018
Statut: ppublish

Résumé

The final stages of polio eradication are proving more difficult than the early phases, and the development of effective drugs and treatments is considered a priority; thus, the research is ongoing. A screening of our in-house chemical library against poliovirus Sabin strains led to the identification of compounds 5 and 6 as hits active at submicromolar concentrations. Derivatives of these compounds were synthesized as a preliminary structure-activity-relationship study. Among them, 7 and 11 were highly active against poliovirus Sabin 1-3. Compound 11 was also very potent against a large panel of wild and vaccine-derived polioviruses. Time-of-addition experiments suggest that 5 and 7 could be active at an early stage of viral replication, whereas 11 was active at same concentration at all stages of viral replication. A ligand-based approach was applied to find the common structural features shared by the new compounds and already-known poliovirus inhibitors.

Identifiants

pubmed: 30512950
doi: 10.1021/acs.jmedchem.8b01482
pmc: PMC9169555
mid: NIHMS1798198
doi:

Substances chimiques

Antiviral Agents 0
Oxazoles 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

798-810

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Références

Biochem Pharmacol. 2012 Jan 15;83(2):185-92
pubmed: 21889497
J Med Chem. 1993 Jun 25;36(13):1811-9
pubmed: 8515420
Antimicrob Agents Chemother. 1990 Mar;34(3):460-6
pubmed: 2159258
Science. 2002 Apr 12;296(5566):356-9
pubmed: 11896235
PLoS One. 2011;6(5):e18360
pubmed: 21904594
J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53
pubmed: 25316866
Acta Crystallogr D Biol Crystallogr. 1997 Sep 1;53(Pt 5):558-70
pubmed: 15299887
J Med Chem. 2011 Apr 28;54(8):2529-91
pubmed: 21413808
Structure. 1997 Jul 15;5(7):961-78
pubmed: 9261087
Antiviral Res. 2014 Oct;110:1-9
pubmed: 25043639
Antimicrob Agents Chemother. 2004 Jun;48(6):2233-43
pubmed: 15155227
Antiviral Res. 2013 May;98(2):186-91
pubmed: 23499651
J Med Chem. 2016 Mar 24;59(6):2780-93
pubmed: 26907951
J Med Chem. 1992 Sep 18;35(19):3483-97
pubmed: 1404230
Antimicrob Agents Chemother. 1992 Jan;36(1):100-7
pubmed: 1317142

Auteurs

Valentina Noemi Madia (VN)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Antonella Messore (A)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Luca Pescatori (L)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Francesco Saccoliti (F)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Valeria Tudino (V)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Alessandro De Leo (A)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Luigi Scipione (L)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Lucia Fiore (L)

Istituto Superiore di Sanità , CRIVIB , Viale Regina Elena 299 , I-00161 Roma , Italy.

Eric Rhoden (E)

Division of Viral Diseases , Centers for Disease Control and Prevention , 1600 Clifton Road , Atlanta , Georgia 30329 , United States.

Fabrizio Manetti (F)

Dipartimento di Biotecnologie Chimica e Farmacia, Dipartimento di Eccellenza 2018-2022 , Università degli Studi di Siena , Via Aldo Moro 2 , I-53100 Siena , Italy.
LDS Lead Discovery Siena Srl , Via Fiorentina 1 , I-53100 Siena , Italy.

M Steven Oberste (MS)

Division of Viral Diseases , Centers for Disease Control and Prevention , 1600 Clifton Road , Atlanta , Georgia 30329 , United States.

Roberto Di Santo (R)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Roberta Costi (R)

Dipartimento di Chimica e Tecnologie del Farmaco, Dipartimento di Eccellenza 2018-2022, Istituto Pasteur-Fondazione Cenci Bolognetti , Sapienza Università di Roma , Piazzale Aldo Moro 5 , I-00185 Roma , Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH